Ritanserin-induced changes in sleep-waking phases in rats

Area of Science:

• Neuroscience
• Pharmacology
• Sleep Medicine

Background:

• Serotonin (5-HT) plays a crucial role in regulating sleep-wake cycles.
• The 5-HT2 receptor subtype is implicated in modulating sleep architecture and behavior.
• Understanding the specific roles of 5-HT receptor subtypes is key to developing targeted sleep therapeutics.

Purpose of the Study:

• To investigate the effects of the 5-HT2 antagonist ritanserin on distinct sleep-wake stages in Wistar rats.
• To elucidate the contribution of 5-HT2 receptors to the regulation of sleep and wakefulness.
• To assess the dose-dependent and time-course effects of ritanserin on sleep architecture.

Main Methods:

• Chronic implantation of electrodes in male Wistar rats for electroencephalographic (EEG) recording.
• Administration of ritanserin at two doses (0.63 mg/kg, 2.5 mg/kg) and vehicle control.
• Visual scoring of six sleep-waking stages (active waking, quiet waking, light slow-wave sleep, deep slow-wave sleep, intermediate sleep, paradoxical sleep) over 12-hour post-drug periods divided into 4-hour intervals.

Main Results:

• Ritanserin significantly reduced wakefulness and paradoxical sleep duration.
• A significant increase in slow-wave sleep, particularly deep slow-wave sleep, and intermediate sleep stages was observed.
• These sleep-wake alterations were dose-dependent, with higher ritanserin doses inducing stronger effects, primarily during the first 4 hours post-administration.

Conclusions:

• 5-HT2 receptor blockade by ritanserin profoundly impacts sleep-wake regulation in rats.
• The findings support a significant role for 5-HT2 receptors in maintaining wakefulness and paradoxical sleep.
• Ritanserin demonstrates potential as a modulator of sleep architecture, with transient effects on most stages, except for a sustained reduction in paradoxical sleep.